Clinical trials: GLP - 1
Overweight, Obesity
Weight and Metabolic Management Study
The goal of this clinical trial is to learn whether elénzia CONTROL®, a nutritional supplement, can support weight management in adults who have either never used GLP-1 weight-loss medications or have recently stopped using them.
- Conditions
- Overweight, Obesity, Weight Maintenance
- Trial name
- WMMS (NCT07789223)
- Testing
- elénzia CONTROL®
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Elenzia
Insulinoma, Nesidioblastosis
68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis
This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-exendin-4 in insulinoma and nesidioblastosis patients.
- Trial name
- NCT02560376
- Testing
- 68Ga-NOTA-exendin-4
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Pulmonary Aspiration During Anaesthetic Induction, Gastric Emptying Time
Gastric Emptying With Metoclopramide in GLP-1 Agonist Patients Undergoing Elective Surgery
This is a multicentre, investigator-blinded, randomised controlled trial evaluating whether the use of oral metoclopramide before surgery can reduce the amount of residual gastric content in patients who are taking glucagon-like…
- Conditions
- Pulmonary Aspiration During Anaesthetic Induction, Gastric Emptying Time, Preoperative Risk Assessment, Obesity (Disorder)
- Trial name
- GEM-GLP1RA (NCT07100691)
- Testing
- Metoclopramide
- Where
- 2 sites in Ireland
- Volunteers
- 80 people
- Sponsor
- Mater Misericordiae University Hospital
Postprandial Hypoglycemia
Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia
It has been proposed that the rapid gastric emptying of carbohydrate containing fluids into the intestine causes hyperglycemia followed by reactive hypoglycemia.
- Trial name
- NCT01162499
- Testing
- Exendin-(9-39), Vehicle
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Diva De Leon
Obesity
Bariatric Surgery Combined With GLP-1RA: A Multicenter Study.
Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with single therapies.
- Trial name
- BS-GLP (NCT07732738)
- Testing
- BS-GLP1RA group, BS group
- Where
- 7 sites in China
- Volunteers
- 400 people
- Sponsor
- China-Japan Friendship Hospital
Obesity & Overweight, Weight Loss
GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study
This research program includes two coordinated prospective studies (FLOURISH and THRIVE) evaluating the real-world effectiveness of Noom's digital health programs on weight, cardiometabolic biomarkers, physiological health…
- Conditions
- Obesity & Overweight, Weight Loss, Preventative Health, Body Weight
- Trial name
- FLOURISH (NCT07588984)
- Testing
- Noom Weight, Free Tier, Education-only control
- Where
- United States
- Volunteers
- 2,310 people
- Sponsor
- Noom Inc.
Coronary Artery Disease, Decreased Left Ventricular Function
Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass
GLP-1 has not only beneficial effects on glucose metabolism but also direct positive effects on cardiac function and metabolism in both experimental models and in patients with type 2 diabetes mellitus.
- Trial name
- Executive (NCT01373216)
- Testing
- Exenatide
- Where
- Czechia
- Volunteers
- 38 people
- Sponsor
- Charles University, Czech Republic
Coronary Angiography, Glucagon-like Peptide-1
Plasma Glucagon-like Peptide-1 Levels and Acute Myocardial Infarction
GLP-1(9-36) amide and (9-37), which was previously thought to be the inactive metabolite of GLP-1, also exerts cardioprotective effects.
- Trial name
- NCT03129594
- Testing
- plasma glucagon-like peptide-1 levels
- Volunteers
- 709 people
- Sponsor
- Chinese PLA General Hospital
Type 2 Diabetes Mellitus
Endothelial and Metabolic Effects of Glucagon-like Peptide-1 (GLP-1) in Coronary Circulation in Patients With Type 2 Diabetes Mellitus
GLP-1 is an incretin hormone which is discharged from the intestines after food intake. The hormone is known for its powerful insulinotropic and trophic effects on the beta cells in the pancreas and is currently used as an…
- Trial name
- NCT00923962
- Testing
- Glucagon like peptide-1, Adenosine
- Where
- Denmark
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Type 2 Diabetes
The Importance of GLP-1 in Post RYGB Improvement in Glycaemic Control Type 2 Diabetic Subjects
After Roux-en-Y gastric bypass (RYGB) meal induced GLP-1 secretion is dramatically increased, while beta-cell function is increased in type 2 diabetic (T2D) subjects.
- Trial name
- NCT01579981
- Testing
- Roux-en-Y Gastric Bypass
- Where
- Denmark
- Volunteers
- 9 people
- Sponsor
- Hvidovre University Hospital
Overweight and Obesity, Healthy
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist
Adult participants with BMI between 22 - 35 kg/m2 will be enrolled and randomized to receive either NG101 (20 mg twice daily [BID]) or placebo for 5 days beginning on Day 1.
- Trial name
- NCT06500429
- Testing
- NG101, Semaglutide Injectable Product
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Neurogastrx, Inc.
Type 2 Diabetes
A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186
This study will assess the safety, tolerability, and pharmacokinetics of AZD0186 following single ascending doses (SAD) via oral administration in healthy adult participants.
- Trial name
- NCT05694741
- Testing
- AZD0186
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes Mellitus Type 2, Metabolic Syndrome
Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients
The most important cause of mortality amongst DM2 patients is cardiovascular disease. An early finding of cardiovascular disease in DM2 and obesity is diastolic dysfunction.
- Conditions
- Diabetes Mellitus Type 2, Metabolic Syndrome, Cardiovascular Disease, Diastolic Dysfunction
- Trial name
- MAGNA VICTORIA (NCT01761318)
- Testing
- Liraglutide
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Leiden University Medical Center
Diabetes Mellitus, Type 2
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JY09
JY09 is a glucagon-like peptide-1 (GLP-1) mimetic generated by genetic fusion of a Exendin-4 dimer to human immunoglobulin Fc. In this Double-blind, randomized, placebo-controlled trial, 41 healthy subjects received placebo or…
- Trial name
- NCT04354090
- Testing
- JY09
- Where
- China
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Beijing Dongfang Biotech Co., Ltd.
Obesity
Co-infusion of Neurotensin and GLP-1 Effects on Appetite and Food Intake.
Co-infusion of Neurotensin and GLP-1 Effects on Appetite and Food Intake.
- Trial name
- NCT04186026
- Testing
- Saline + saline, Neurotensin + saline, GLP-1 + saline
- Where
- 2 sites in Denmark
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Type 2 Diabetes Mellitus (T2DM)
Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy
DM200-103 is a dose-ranging study to evaluate the efficacy and safety of 17 weeks of weekly injections of CJC-1134-PC in patients with Type 2 Diabetes Mellitus on metformin monotherapy.
- Trial name
- NCT01514149
- Testing
- CJC-1134-PC Injection
- Where
- 22 sites in United States, Canada
- Volunteers
- 73 people
- Sponsor
- ConjuChem
Type 2 Diabetes
Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study, which aims to provide data on the efficacy and safety of HDM1002 tablets in adults with type 2 diabetes mellitus (T2DM) inadequately…
- Trial name
- NCT07193459
- Testing
- HDM1002 200 mg, HDM1002 400 mg
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Chronic Kidney Disease, Type 2 Diabetes
RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)
The goal of this pragmatic randomized clinical trial is to determine whether an Epic-based clinician notification increases initiation of guideline-directed cardio-kidney-metabolic (CKM) therapies in adults with type 2 diabetes…
- Trial name
- NCT07605390
- Testing
- Epic-Based Clinician Notification, Usual Care
- Where
- 2 sites in United States
- Volunteers
- 600 people
- Sponsor
- Baylor Research Institute
Idiopathic Intracranial Hypertension, Intracranial Pressure
The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure
50 patients with verified new-onset Idiopathic Intracranial Hypertension are randomly allocated to standard weight management (dietician counselling) or trial intervention consisting of subcutaneous injections with Semaglutide…
- Conditions
- Idiopathic Intracranial Hypertension, Intracranial Pressure, Obesity, Pseudotumor Cerebri Syndrome
- Trial name
- IIH:DUAL (NCT06027567)
- Testing
- Semaglutide, Very Low Calorie Diet, Dietician counselling
- Where
- 2 sites in Denmark
- Volunteers
- 38 people
- Sponsor
- Rigmor Højland Jensen
Type 2 Diabetes Mellitus
Tofogliflozin GLP-1 Analogue Combination Trial
An open-label, multicenter study to evaluate 52-week long-term safety, tolerability and efficacy of Tofogliflozin with GLP-1 analogue treatment in type 2 diabetes mellitus.
- Trial name
- NCT02537834
- Testing
- Tofogliflozin, GLP-1 analogue
- Where
- 11 sites in Japan
- Volunteers
- 65 people
- Sponsor
- Kowa Company, Ltd.